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Increased extracellular matrix (ECM) protein deposi-
tionandcapillarybasementmembrane(BM)thickeningare
characteristic features of diabetic retinal microangiopathy.
Recent observations in the authors’ laboratories suggest
that high glucose in endothelial cells as well as diabetes
causes up-regulation of total ﬁbronectin (FN), as well as
extradomain-B (EDB) containing the spliced variant of FN,
oncofetal FN, in the retina. This splice variant is normally
absent in mature adult tissues and is believed to be in-
volved in angiogenesis. In this study, the authors have in-
vestigated the role of C-peptide in the production of ECM
proteins and capillary BM thickening in the retina of dia-
betic rats. They investigated retinas from poorly controlled
diabetic BB/Wor rats with or without C-peptide treatment
as well as those from age-matched nondiabetic control rats
after 8 months of diabetes. In addition, the authors inves-
tigated retinas from BBDRZ/Wor rats, a model of type 2
diabetes. Following a treatment period of 8 months, reti-
nal tissues were harvested for gene expression and histo-
logical analyses. In the retinas of diabetic BB/Wor rats, a
signiﬁcantincreaseofoncofetalFNwasdemonstratedcom-
pared to control rats. C-peptide treatment of BB/Wor rats
completely prevented such increase. Furthermore, retinas
from BBDRZ/Wor rats, did not exhibit any such alteration
in oncofetal FN expression. The authors further examined
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retinal capillary BM thickening using ultrastructural
morphometry. C-peptide treatment was ineffective in pre-
ventingthediabetes-inducedincreaseincapillaryBMthick-
ness. The authors’ previous studies of cultured endothe-
lial cells demonstrated that oncofetal FN synthesis is, at
least in part, mediated via transforming growth factor-β
(TGF-β) and endothelin-1 (ET-1). Hence, they examined
thesetwotranscriptsintheretinaoftheseanimals.Diabetes
causedsigniﬁcantincreaseinmRNAexpressionofET-1and
TGF-β, which was not prevented by C-peptide treatment.
Hence it appears that C-peptide is effective in preventing
diabetes-inducedoncofetalFNexpressionandthattheseef-
fects are not mediated via ET-1 or TGF-β. In conclusion,
these data suggest that C-peptide is involved in regulating
ECM protein composition. Furthermore, normalization of
diabetes-induced oncofetal FN up-regulation may suggest
importanceofC-peptideinadvancedalterationsindiabetic
retinopathy such as angiogenesis.
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INTRODUCTION
Long-term complications of diabetes are as debilitating as
the disease itself. Patients with diabetes develop secondary
complications, such as nephropathy, neuropathy, and retinopa-
thy (Brownlee, 2001). Diabetic retinopathy (DR) progresses
through the background, to preproliferative, and ﬁnally the
proliferative stages (Sheetz and King, 2002). Hyperglycemia
is associated with the initiation as well as the progression of
DR (The Diabetes Control and Complications Trial Research
Group, 1993; UK Prospective Diabetes Study Group, 1998).
Several biochemical abnormalities are associated with hyper-
glycemia,includingincreasesinoxidativestress,nonenzymatic
glycation of proteins, activation of the polyol pathway, and
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up-regulation of growth factors, vasoactive peptides, and cy-
tokines (Cai and Boulton, 2002). Pathologically, the result of
such biochemical changes include the loss of retinal capillary
pericytes, which leads to the formation of capillary ghosts, the
thickening of retinal capillary basement membrane (BM), and
neovascularization (Tsilibary, 2003). Capillary BM thickening
is one of the hallmarks of diabetic retinal microangiopathy
(Tsilibary, 2003). We have previously demonstrated that BM
thickening is accompanied by increased alpha-1 (IV) collagen
and ﬁbronectin expression (Evans et al., 2000).
Fibronectin (FN) is one extracellular protein that is up-
regulated due to diabetes. FN is a dimeric protein produced
as a soluble form, which is secreted into the blood (plasma
FN), and a nonsoluble isoform, which is cross-linked and de-
posited within the extracellular matrix (ECM) (cellular FN)
(Kornblihtt et al., 1996). The FN dimer is composed of non-
identical polypeptides of 250 to 280 KDa, made up of type I
(40 amino acid [aa] residues), type II (60 aa residues), and
type III (90 aa residues) repeats. The single rat and human
FN gene can produce several isoforms (12 in the rat, 20 in hu-
mans)bywayofaltenativesplicing(Schwarzbaueretal.,1983;
Kornblihtt et al., 1984).
Within the FN gene, an area of variability (EDB or EIIIB)
encodes a single exon that translates to a highly conserved
type III repeat (Zardi et al., 1987). This EDB-encoded area
is not found in plasma FN, but is found in embryonic tissue and
transformed cells. Hence, this FN isoform is known as oncofe-
tal FN (Carnemolla et al., 1989; Zardi et al., 1987). We have
recently demonstrated that oncofetal FN is up-regulated both
in human and animal diabetes (Khan et al., 2004).
Along with hyperglycemia, type 1 diabetes show a lack of
insulin and C-peptide. C-peptide is the spacer protein that is
cleaved from proinsulin, allowing the correct conformational
folding of insulin for secretion and interaction with the insulin
receptor (Wahren et al., 2000). Initially believed to possess no
otherbiologicalrolethaninsulinsynthesis(Kitabchi,1977),the
opinion of C-peptide as a biologically inactive molecule has
changed based on recent research. C-peptide treatment lead-
ing to increased Na+/K+-ATPase activity, mitogen-activated
protein kinase (MAPK) activity, Ca2+ inﬂux, endothelial ni-
tric oxide synthase (eNOS) activity, phosphoinositide 3-kinase
(PI3K), and protein kinase C (PKC) activity has been demon-
strated in the context of diabetes (Grunberger et al., 2001;
Johansson et al., 2002; Li et al., 2001, 2003; Wahren et al.,
2000).
Animal experiments with C-peptide–treated streptozotocin
(STZ)-induceddiabeticratshaveresultedinimprovedglomeru-
lar hyperﬁltration and decreased protein leakage (Samnegard
et al., 2001; Sjoquist et al., 1998). Similar data have been
demonstrated in human diabetes (Johansson et al., 1992).
STZ-diabetic animals treated with C-peptide showed improve-
ments in diabetes-induced reduced motor nerve conduction
velocity and reduced sciatic nerve Na+,K+-ATPase activity
(Cameronetal.,2001;Idoetal.,1997;Simaetal.,2001).Inthe
type I BB/Wor rat, C-peptide replacement prevented small and
large ﬁber functional deﬁcits as well as structural changes of
peripheral nerve (Sima et al., 2001; Sima, 2003; Pierson et al.,
2003). In the retina, C-peptide treatment has been shown to im-
prove retinal blood ﬂow and reduce vascular permeability (Ido
et al., 1997). However, no data are available as to the possible
role of C-peptide in ECM protein production and subsequent
capillary BM thickening.
In this report, we determined the effects of long-term
C-peptidetreatmentontheexpressionoftheECMproteins,FN,
and oncofetal FN, and capillary BM thickening in the retina of
the diabetic BB/Wor rat.
C-PEPTIDE AND FIBRONECTIN EXPRESSION
Using speciﬁc and sensitive real time reverse transcriptase–
polymerase chain reaction (RT-PCR) assay (Chen et al., 2003),
we have investigated whether C-peptide regulates expression
of FN and oncofetal FN. RNA was extracted from frozen reti-
nal tissues and subjected to RT-PCR as previously described
(Chen et al., 2003). Retinas of male BB/Wor diabetic rats
after 8 months of diabetes exhibited increased expression of
total FN as well as relative oncofetal FN (oncofetal FN:total
FN) as compared to age and sex-matched nondiabetic controls
(Figure 1). Interestingly, C-peptide treatment (75 ng/kg/day;
Pierson et al., 2003) of BB/Wor rats completely normalized the
diabetes-induced oncofetal FN up-regulation (Figure 1). Fur-
ther, in support of the potential role of C-peptide in ECM pro-
tein alterations, retinas from BBDRZ/Wor rats (model of type
II diabetes with normal C-peptide levels) showed no alteration
in oncofetal FN expression levels.
C-PEPTIDE REGULATES ECM PROTEIN
EXPRESSION INDEPENDENT OF TGF-β1
AND ET-1
Our previous studies have demonstrated that glucose-
inducedoncofetalFNexpressioninvascularendothelialcellsis,
inpart,mediatedviatransforminggrowthfactor-β (TGF-β)and
endothelin-1(ET-1)(Khanetal.,2004).Inaddition,TGF-β has
been shown to regulate the preferential expression of oncofetal
FN in various tissues during remodeling and wound healing
(Jarnagin et al., 1994; Nickeleit et al., 1996). We determined
whether these potent mitogenic growth factors are transducers
of C-peptide signals in regulating oncofetal FN in retinas of
C-peptide–treated diabetic animals. Retinal tissues of BB/Wor
diabetic animals showed signiﬁcantly increased mRNA levelsC-PEPTIDE AND RETINAL MICROANGIOPATHY 93
FIGURE 1
Effect of C-peptide on expression of FN isoforms in retina. Quantiﬁcation of FN mRNA expression in retinal tissues by real time
RT-PCR, showing (A) total FN and (B) oncofetal FN. Total FN mRNA levels are expressed as ratio of target mRNA to β-actin.
Oncofetal FN levels are expressed as ratio of isoform mRNA to total FN mRNA. (C) Melting curve analysis (MCA) of oncofetal
FN post-PCR products. MCA was used to determine speciﬁcity of PCR reactions (a single peak denotes speciﬁc dsDNA species
in the reaction mixture). C = controls; D = BB/Wor rats; D-Cpep = BB/Wor diabetic rats treated with C-peptide;
BBDRZ/Wor= BBDRZ/Wor-rats. ∗P <. 05 compared to controls; †P <. 05 compared to BB/Wor animals; n = 6/group.
of both ET-1 and TGF-β (Figure 2). C-peptide treatment of
thesediabeticanimalsfailedtoalterdiabetes-inducedET-1and
TGF-β expression (Figure 2). In addition, retinal tissues from
BBDRZ/Wor diabetic rats exhibited increased levels of both
ET-1 and TGF-β transcripts as compared to control rats and
increased ET-1 expression compared to type I BB/Wor dia-
betic rats. These ﬁndings suggest that C-peptide may regulate
expression of oncofetal FN via ET-1 and TGF-β–independent
mechanisms.
C-PEPTIDE AND RETINAL CAPILLARY
BM THICKENING
Increased expression of FN has been shown to be instru-
mental in mediating structural alterations and capillary BM
thickening in retinas of diabetic rats (Evans et al., 2000). In
both animal and human diabetes, we and others have demon-
strated up-regulation of FN in target organs of chronic com-
plications, including the retina (Evans et al., 2000; Roy et al.,
1996). We examined whether C-peptide–mediated normaliza-
tion of oncofetal FN was associated with prevention of cap-
illary BM thickening in BB/Wor diabetic rats. Retinal tissues
from animals were ﬁxed in 2.5% gluteraldehyde and processed
forelectronmicroscopy.Retinalcapillariesfromthedeepcapil-
lary bed were analyzed by orthogonal intercept method for BM
thickening (Evans et al., 2000). C-peptide treatment was found
to be ineffective in preventing diabetes-induced increases in
retinalcapillaryBMthickening(Figure3).Furthermore,type2
BBDRZ/WordiabeticanimalsexhibitedBMthickeningsimilar
to that of untreated BB/Wor rats.94 S. CHAKRABARTI ET AL.
FIGURE 2
Effect of C-peptide on TGF-β1 and ET-1 expression.
Quantiﬁcation of ﬁbrogenic growth factor expression in retinal
tissues by real time RT-PCR quantiﬁcation, showing
(A) TGF-β1 and (B) ET-1 mRNA levels. TGF-β1 and ET-1
mRNA levels are expressed as ratio of target mRNA to β-actin.
C = controls; D = BB/Wor rats; D-Cpep = BB/Wor diabetic
rats treated with C-peptide; BBDRZ/Wor = BBDRZ/Wor-rats.
∗P <. 05 compared to control; †P <. 05 compared to
BB/Wor-animals; n = 6/group.
DISCUSSION
The mechanisms by which C-peptide mediates extracellu-
lar signals is not fully understood. Radioligand-binding stud-
ies in rats indicate that C-peptide binds to islet cells (Flatt
et al., 1986). Furthermore, using more sophisticated ﬂuores-
cence spectroscopy technique, human C-peptide was shown to
bind to cell membrane preparations from various cell types,
including renal tubular cells and vascular endothelial cells
(Henriksson et al., 2001; Pramanik et al., 2001; Rigler et al.,
1999).RecentstudiesalsosuggestthatC-peptidepossiblybinds
tocellsurfacereceptorscoupledtoG-proteins(Johanssonetal.,
2002; Ohtomo et al., 1996; Shafqat et al., 2002). In support of
such notion is the observation that C-peptide increases inﬂux
of extracellular calcium. This inﬂux is completely abolished
by treating cells with pertussis toxin. Furthermore, potential
downstream mediators of C-peptide signaling seem to include
members of MAPK pathway, extracellular signal-regulated
kinase (ERK) 1 and 2 (Kitamura et al., 2003). Treatment of ﬁ-
broblasts with C-peptide leads to phosphorylation of ERK 1/2,
which is normalized by pertussis toxin and the MAPK in-
hibitor, PD098059. Furthermore, accumulating evidence sug-
FIGURE 3
Effect of C-peptide on capillary basement membrane
thickening. (A) Analysis of retinal basement membranes
indicates a diabetes-induced increase in basement membrane
thickening in both BB/Wor and BBDRZ/Wor rats after
8 months. C-peptide therapy was not effective in preventing
diabetes-induced increased BM thickening. The lower panel
shows representative electron micrographs of the retinal
capillary from control (B) and diabetic rats (C). C = controls;
D = BB/Wor rats; D-Cpep = BB/Wor diabetic rats treated
with C-peptide; BBDRZ/Wor = BBDRZ/Wor-rats. ∗P <. 05
compared to control; n = 6/group. Bar = 230 nm.
gests that C-peptide–mediated activation of ERK 1/2 and cal-
cium inﬂux could potentially cross-talk with PKC and PI3K
activation (Kitamura et al., 2001). Furthermore, we have pre-
viously demonstrated that C-peptide increases autophosphory-
lation of the insulin receptor and increases the insulin recep-
tor tyrosine kinase activity (Grunberger et al., 2001; Li et al.,
2001, 2003). In addition, C-peptide increases insulin-receptor
substrate-1 (IRS-1) phosphorylation and MAPK, and PI3K ac-
tivities. These effects resulted in increased glycogen synthesis
and amino acid uptake (Grunberger et al., 2001). These effects
were diminished by wortmannin (PI3K and MAPK inhibitor),
whereas pertussis toxin had no effects. These effects were in-
duced by C-peptide alone and C-peptide potentiated the same
effects by insulin, strongly suggesting that C-peptide has in-
sulinomimetic effects (Grunberger et al., 2001; Li et al., 2003).
Many C-peptide effects, such as phosphorylation and
increased activity of MAPK, PI3K, and PKC, are well
characterized in the context of diabetic complications,
including retinopathy. Such pathways could potentially arbi-
trate increased ECM protein deposition. However, our studiesC-PEPTIDE AND RETINAL MICROANGIOPATHY 95
indicate that C-peptide reduces diabetes-induced oncofetal FN
expression. Previous studies have shown that C-peptide acti-
vates eNOS and prevents diabetes-induced vascular permeabil-
ity in the retina (Ido et al., 1997). It is plausible that C-peptide
prevents vascular dysfunction. Our ﬁndings do support such
a notion, in that C-peptide normalized oncofetal FN expres-
sion, which has been associated with activated endothelium but
is ineffective against hyperglycemia-induced ET-1 and TGF-β
expression.
Our data demonstrate that C-peptide treatment was ineffec-
tive in reducing capillary BM thickening. In addition, BBDRZ/
Wor rats showed higher BM thickness similar to that of un-
treatedBB/Woranimals.Itisoffurtherinteresttonotethattotal
and oncofetal FN levels were lower in the BB/Wor rats replen-
ished with C-peptide as well as in BBDRZ/Wor rats compared
to untreated BB/Wor rats. These data suggest that several other
factorsmaybeinvolvedincapillaryBMthickening,whichmay
not be prevented by C-peptide therapy. This notion, however,
needs to be conﬁrmed with further experiments.
The effect of C-peptide on reduced oncofetal FN and total
FN mRNA expression may have signiﬁcant implications. FN
is involved in the regulation of various cellular events through
interaction with cell surface receptors (Kornblihtt et al., 1996).
Thesecellulareventsincludecellmigrationandproliferationof
ﬁbroblasts and endothelial cells. Expression of FN containing
the EDB segment is highly regulated, being exclusive to em-
bryonic and tumor tissues (Zardi et al., 1987). This oncofetal
isoform of FN has recently been proposed to be an angiogenic
marker. We have previously demonstrated that oncofetal FN
is involved in proliferation of vascular endothelial cells (Khan
et al., 2004). In addition, we have shown that oncofetal FN is
up-regulated in vitreous specimens from patients with prolifer-
ativediabeticretinopathy.OurﬁndingsofreducedoncofetalFN
expressioninretinasofdiabeticratstreatedwithC-peptidesug-
gest potential novel avenues for the development of therapeutic
modalities.
Our studies do indicate that C-peptide possesses important
biological activity and is involved in regulating ECM protein
composition.ItisincreasinglybeingrealizedthatECMismore
than a mere bystander. The composition of the ECM is impor-
tant in various physiological and pathological conditions and
is a function of the tissue microenvironment (Badylak, 2002).
In the context of proliferative diabetic retinopathy, the com-
position of ECM could potentially confer an angiogenic phe-
notype on vascular endothelial cells. Recent studies do sup-
port the notion that the composition and physical properties of
ECMcanmodulateendothelialcellbehavior,facilitatingangio-
genesis. Our studies indicate that C-peptide is able to reduce
diabetes-induced oncofetal FN expression. We have previously
demonstrated that oncofetal FN is involved in proliferation of
endothelialcells(Khanetal.,2004).Itisplausiblethatincreased
circulating C-peptide levels in patients with type 2 diabetes re-
duces oncofetal FN expression in the retina, which could offer
some explanation of the disparity in the prevalence and pro-
gression to proliferative diabetic retinopathy in type 1 and type
2 diabetic patients (Keen et al., 2001).
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